Pulmonary delivery of nanosized alendronate for decorporation of inhaled heavy metals: formulation development, characterization and gamma scintigraphic evaluation

References

• Grandjean P. Even low-dose lead exposure is hazardous. Lancet 2010;376:855–856
   PubMedGoogle Scholar
• Kerin EJ, Lin HK. Fugitive dust and human exposure to heavy metals around the Red Dog Mine. Rev Environ Contam Toxicol 2010;206:49–63
   PubMed Web of Science ®Google Scholar
• Wang Z, Chai L, Yang Z, et al. Identifying sources and assessing potential risk of heavy metals in soils from direct exposure to children in a mine-impacted city, Changsha, China. J Environ Qual 2010;39:1616–1623
   PubMed Web of Science ®Google Scholar
• Henge-Napoli MH, Stradling GN, Taylor DM. Decorporation of radionuclides from the human body. Radiat Prot Dosimetry 2000;87:9–17
   Google Scholar
• James AC, Sasser LB, Stuit DB, et al. Ustur whole body case 0269: demonstrating effectiveness of i.v. Ca-DTPA for Pu. Radiat Prot Dosimetry 2007;127:449–455
   PubMed Web of Science ®Google Scholar
• Dogana I, Ocakb M, Cansiz T, et al. 99mTc-labeling of alendronate: a new potent biphosphonate. ISTR, IAEA-CN-130/115P 2005; 235
   Google Scholar
• Russell RGG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119:150–162
   PubMed Web of Science ®Google Scholar
• Xu K, Ge W, Liang G, et al. Bisphosphonate-containing supramolecular hydrogels for topical decorporation of uranium-contaminated wounds in mice. Int J Radiat Biol 2008;84:353–362
   PubMed Web of Science ®Google Scholar
• Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8:96–110
   PubMedGoogle Scholar
• Cebrian D, Tapia A, Real A, Morcillo MA. Inositol hexaphosphate: a potential chelating agent for uranium. Radiat Prot Dosimetry 2007;127:477–479
   PubMed Web of Science ®Google Scholar
• Gumienna-Kontecka E, Silvagni R, Lipinski R, et al. Bisphosphonate chelating agents: complexation of Fe(III) and Al(III) by 1-phenyl-1-hydroxymethylene bisphosphonate and its analogues. Inorganica Chimica Acta 2002;339:111–118
   Web of Science ®Google Scholar
• Houpert P, Chazel V, Paquet F. A local approach to reduce industrial uranium wound contamination in rats. Can J Physiol Pharmacol 2004;82:73–78
   PubMedGoogle Scholar
• Xu GY, Yang CH, Liu B, et al. Catechol-bisphosphonate conjugates: new potential chelating agents for metal intoxication therapy. Chinese Chem Lett 2004;15:1403–1406
   Google Scholar
• Deubner DC, Sabey P, Huang W, et al. Solubility and chemistry of materials encountered by beryllium mine and ore extraction workers: relation to risk. J Occup Environ Med 2011;53:1187–1193
   PubMed Web of Science ®Google Scholar
• Murray J, Davies T, Rees D. Occupational lung disease in the South African mining industry: research and policy implementation. J Public Health Policy 2011;32:S65–S79
   Google Scholar
• Sultana S, Talegaonkar S, Ali R, et al. Inhalation of alendronate nanoparticles as dry powder inhaler for treatment of osteoporosis. J Microencapsul 2012;29:445–454
   PubMed Web of Science ®Google Scholar
• Bhavna, Ahmad FJ, Mittal G, et al. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constructive conditions. Eur J Pharm Biopharm 2009;71:282–291
   PubMed Web of Science ®Google Scholar
• Shekunov BY, Chattopadhyay P, Tong HHY, Chow AHL. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm Res 2007;24:203–226
   PubMed Web of Science ®Google Scholar
• Ali R, Jain GK, Iqbal Z, et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine: NBM 2009;5:55–63
   PubMed Web of Science ®Google Scholar
• Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery – a review for multidisciplinary researchers. Med Eng Phys 2012;34:409–427
   PubMed Web of Science ®Google Scholar
• Kumar N, Soni S, Jaimini A, et al. Edetate calcium disodium nanoparticle dry powder inhalation: a novel approach against heavy metal decorporation. Int J Pharm 2011;416:376–383
   PubMed Web of Science ®Google Scholar
• Sultana S, Talegaonkar S, Mittal G, et al. Determination of alendronate sodium by Box–Behnken statistical design. Chromatographia 2010;72:321–326
   Google Scholar
• Mittal G, Singh T, Goomer NC, et al. Formulations and methods thereof for making radiolabeled dry powder. 2008; Patent No. 1536/DEL/2008
   Google Scholar
• Singh AK, Verma J, Bhatnagar A, et al. Tc-99m Isoniazid: A specific agent for diagnosis of tuberculosis. World J Nucl Med 2003;2:292–305
   Google Scholar
• Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 1997;10:187–198
   Google Scholar
• Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products. J Pharm Int 2000;208:49–60
   PubMed Web of Science ®Google Scholar
• Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 2009;29:196–212
   PubMed Web of Science ®Google Scholar
• Al-Hallak MH, Sarfraz MK, Azarmi S, et al. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther Deliv 2011;2:1313–1324
   PubMedGoogle Scholar
• Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1:67–86
   PubMedGoogle Scholar
• Tsujikawa T, Andoh A, Inatomi O, et al. Alendronate improves low bone mineral density induced by steroid therapy in Crohn’s disease. Inter Med 2009;48:933–937
   PubMedGoogle Scholar
• Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555–1565
   PubMed Web of Science ®Google Scholar
• Sawicki M, Lecerclé D, Grillon G, et al. Bisphosphonate sequestering agents. Synthesis and preliminary evaluation for in vitro and in vivo uranium(VI) chelation. Eur J Med Chem 2008;43:2768–2777
   PubMed Web of Science ®Google Scholar
• Taylor A, Gustafsson P. Do all dry powder inhalers show the same pharmaceutical performance? Int J Clin Pract Suppl 2005;149:7–12
   Google Scholar
• Türker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004;26:137–142
   PubMed Web of Science ®Google Scholar
• Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640–1665
   PubMed Web of Science ®Google Scholar